Linker ID	LIN00041
Linker Name	(6-maleimidocaproyl) hydrazone derivative
Linker Type	Enzyme-sensitive linkers
Structure
	2D MOL
Formula	C12H19N3O4S
#Ro5 Violations (Lipinski): 0	Molecular Weight (mw)			301.368
	Lipid-water partition coefficient (xlogp)			-0.3016
	Hydrogen Bond Donor Count (hbonddonor)			3
	Hydrogen Bond Acceptor Count (hbondacc)			6
	Rotatable Bond Count (rotbonds)			8
Canonical smiles	O=C(CCCCCN1C(=O)CC(S)C1=O)NN=CCO
InChI	InChI=1S/C12H19N3O4S/c16-7-5-13-14-10(17)4-2-1-3-6-15-11(18)8-9(20)12(15)19/h5,9,16,20H,1-4,6-8H2,(H,14,17)/b13-5-
InChIKey	VWBYZCVBANWODJ-ACAGNQJTSA-N

Experiment 1 Reporting the Activity Data of This PDC					[1]
Indication	Tumor
Efficacy Data	Retarded the tumor growth rate	47.09%
Administration Time	20 days
Administration Dosage	3.0 mg/kg doxorubicin equivalent
Description	The doxorubicin, DOXO-EMCH, ABD-RGDK-DOXO, and ABD-RPARPAR-DOXO retarded the tumor growth rate by 24.28, 25.67, 47.78, and 47.09% on day 20, respectively.
In Vivo Model	Tumor-bearing BALB/c nude mice.
Half life period	23.88 ± 0.94 h

Experiment 1 Reporting the Activity Data of This PDC					[1]
Indication	Tumor
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	11.21 ± 4.54 µM
Evaluation Method	CCK-8 assay
Description	Whereas conjugation of a peptide would hinder the passive diffusion route, resulting in higher IC50 values for the peptide-DOX-conjugates (9.27 ± 3.56 uM for ABD-RGDK-DOXO and 11.21 ± 4.54 uM for ABD-RPARPAR-DOXO, respectively).
In Vitro Model	Lung adenocarcinoma	A-549 cell		CVCL_0023
Half life period	23.88 ± 0.94 h

Experiment 1 Reporting the Activity Data of This PDC					[1]
Indication	Tumor
Efficacy Data	Retarded the tumor growth rate	47.78%
Administration Time	20 days
Administration Dosage	3.0 mg/kg doxorubicin equivalent
Description	The doxorubicin, DOXO-EMCH, ABD-RGDK-DOXO, and ABD-RPARPAR-DOXO retarded the tumor growth rate by 24.28, 25.67, 47.78, and 47.09% on day 20, respectively.
In Vivo Model	Tumor-bearing BALB/c nude mice.
Half life period	23.67 ± 0.35 h

Experiment 1 Reporting the Activity Data of This PDC					[1]
Indication	Tumor
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	9.27 ± 3.56 µM
Evaluation Method	CCK-8 assay
Description	Whereas conjugation of a peptide would hinder the passive diffusion route, resulting in higher IC50 values for the peptide-DOX-conjugates (9.27 ± 3.56 uM for ABD-RGDK-DOXO and 11.21 ± 4.54 uM for ABD-RPARPAR-DOXO, respectively).
In Vitro Model	Lung adenocarcinoma	A-549 cell		CVCL_0023
Half life period	23.67 ± 0.35 h

Ref 1	Albumin Binding Domain Fusing R/K-X-X-R/K Sequence for Enhancing Tumor Delivery of Doxorubicin. Mol Pharm. 2017 Nov 6;14(11):3739-3749. doi: 10.1021/acs.molpharmaceut.7b00497. Epub 2017 Oct 9.